Leiden University Scholarly Publications

Your Search

Enabled Filters

  • (-) = Luijtens, K.

Search results

  • RSS Feed
(1 - 12 of 12)
Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials
Combe, B.; Furst, D.E.; Keystone, E.C.; Heijde, D. van der; Luijtens, K.; Ionescu, L.; ... ; Emery, P. 2016
Certolizumab Pegol Efficacy Across Methotrexate Regimens: A Pre-Specified Analysis of Two Phase III Trials
Article / Letter to editor
metadata only
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
Weinblatt, M.E.; Fleischmann, R.; Vollenhoven, R.F. van; Emery, P.; Huizinga, T.W.J.; Cutolo, M.; ... ; Dougados, M. 2015
Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population
Article / Letter to editor
metadata only
TIMING AND MAGNITUDE OF INITIAL RESPONSE TO CERTOLIZUMAB PEGOL IN A BROAD POPULATION OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS PREDICTS LIKELIHOOD OF LDA AT WEEK 28
Weinblatt, M.E.; Fleischmann, R.; Davies, O.; Luijtens, K.; Heijde, D. van der 2013
TIMING AND MAGNITUDE OF INITIAL RESPONSE TO CERTOLIZUMAB PEGOL IN A BROAD POPULATION OF PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS PREDICTS LIKELIHOOD OF LDA AT WEEK 28
Article / Letter to editor
metadata only
Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial
Keystone, E.C.; Combe, B.; Smolen, J.; Strand, V.; Goel, N.; Vollenhoven, R. van; ... ; Heijde, D. van der 2012
Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial
Article / Letter to editor
metadata only
Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial
Heijde, D. van der; Keystone, E.C.; Curtis, J.R.; Landewe, R.B.; Schiff, M.H.; Khanna, D.; ... ; Furst, D.E. 2012
Timing and Magnitude of Initial Change in Disease Activity Score 28 Predicts the Likelihood of Achieving Low Disease Activity at 1 Year in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol: A Post-hoc Analysis of the RAPID 1 Trial
Article / Letter to editor
metadata only
CERTOLIZUMAB PEGOL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ALIGNED WITH NICE GUIDANCE FOR ANTI-TNF THERAPY: POST-HOC ANALYSES OF THE REALISTIC PHASE IIIB RANDOMIZED CONTROLLED STUDY
Weinblatt, M.E.; Fleischmann, R.; Vollenhoven, R. van; Emery, P.; Huizinga, T.W.J.; Goldermann, R.; ... ; Dougados, M. 2012
CERTOLIZUMAB PEGOL IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS ALIGNED WITH NICE GUIDANCE FOR ANTI-TNF THERAPY: POST-HOC ANALYSES OF THE REALISTIC PHASE IIIB RANDOMIZED CONTROLLED STUDY
Article / Letter to editor
metadata only
Efficacy Sustained After Dose De-escalation of Certolizumab Pegol in Rheumatoid Arthritis Patients: Post-hoc Analysis of the RAPID 2 Open-label Extension
Smolen, J.; Vollenhoven, R. van; Kavanaugh, A.; Luijtens, K.; Heijde, D. van der; Curtis, J. 2011
Efficacy Sustained After Dose De-escalation of Certolizumab Pegol in Rheumatoid Arthritis Patients: Post-hoc Analysis of the RAPID 2 Open-label Extension
Other
metadata only
Time to and Level of Initial DAS28 Change With Certolizumab Pegol Predicts the Likelihood of Having Low Disease Activity at Years 1 and 2 in Patients With Rheumatoid Arthritis
Haraoui, B.; Heijde, D. van der; Schiff, M.; Keystone, E.; Landewe, R.; Kvien, T.; ... ; Furst, D. 2011
Time to and Level of Initial DAS28 Change With Certolizumab Pegol Predicts the Likelihood of Having Low Disease Activity at Years 1 and 2 in Patients With Rheumatoid Arthritis
Other
metadata only
PROBABILITY OF ACHIEVING LOW DISEASE ACTIVITY AT 52 WEEKS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL DEPENDS ON TIME TO AND LEVEL OF INITIAL RESPONSE
Heijde, D. van der; Schiff, M.; Keystone, E.; Landewe, R.; Kvien, T.; Curtis, J.; ... ; Furst, D. 2011
PROBABILITY OF ACHIEVING LOW DISEASE ACTIVITY AT 52 WEEKS IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH CERTOLIZUMAB PEGOL DEPENDS ON TIME TO AND LEVEL OF INITIAL RESPONSE
Other
metadata only
EFFICACY SUSTAINED AFTER DOSE DE-ESCALATION OF CERTOLIZUMAB PEGOL IN RHEUMATOID ARTHRITIS PATIENTS: POST-HOC ANALYSIS OF THE RAPID 2 OPEN-LABEL EXTENSION
Smolen, J.; Vollenhoven, R. van; Kavanaugh, A.; Luijtens, K.; Heijde, D. van der; Curtis, J. 2011
EFFICACY SUSTAINED AFTER DOSE DE-ESCALATION OF CERTOLIZUMAB PEGOL IN RHEUMATOID ARTHRITIS PATIENTS: POST-HOC ANALYSIS OF THE RAPID 2 OPEN-LABEL EXTENSION
Other
metadata only
Incremental Benefit of Open-Label Certolizumab Pegol plus MTX in Rheumatoid Arthritis (RA) Patients Following Double-Blind Placebo plus IVITX Treatment Out to 2 Years
Combe, B.; Schwartzman, S.; Massarotti, E.; Keystone, E.; Luijtens, K.; Heijde, D. van der 2010
Incremental Benefit of Open-Label Certolizumab Pegol plus MTX in Rheumatoid Arthritis (RA) Patients Following Double-Blind Placebo plus IVITX Treatment Out to 2 Years
Other
metadata only
INCREMENTAL BENEFIT OF OPEN-LABEL CERTOLIZUMAB PEGOL plus MTX IN RHEUMATOID ARTHRITIS (RA) PATIENTS FOLLOWING DOUBLE-BLIND PLACEBO plus MTX TREATMENT OUT TO 2 YEARS
Combe, B.; Schwartzman, S.; Massarotti, E.; Keystone, E.C.; Luijtens, K.; Heijde, D. van der 2010
INCREMENTAL BENEFIT OF OPEN-LABEL CERTOLIZUMAB PEGOL plus MTX IN RHEUMATOID ARTHRITIS (RA) PATIENTS FOLLOWING DOUBLE-BLIND PLACEBO plus MTX TREATMENT OUT TO 2 YEARS
Other
metadata only